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Abstract
Background: Sialyl Lewis x (sLex) antigen is a carbohydrate antigen that is considered not only a marker for cancer but
also implicated functionally in the malignant behaviour of cancer cells. Overexpression of sLex is associated with enhanced
progression and metastases of many types of cancer including those of the mammary gland. Canine mammary tumours
can invade and give rise to metastases via either lymphatic or blood vessels.
E-Cadherin is specifically involved in epithelial cell-to-cell adhesion. In cancer, E-Cadherin underexpression is one of the
alterations that characterizes the invasive phenotype and is considered an invasion/tumour suppressor gene. Partial or
complete loss of E-Cadherin expression correlates with poor prognosis in canine malignant mammary cancer.
The aim of this study was to analyse the sLex expression in canine malignant mammary tumours and to evaluate if the
presence of sLex correlates with the expression of E-Cadherin and with clinicopathological features.
Methods: Fifty-three cases of canine mammary carcinomas were analysed immunohistochemically using monoclonal
antibodies against sLex (IgM) and E-Cadherin (IgG). The clinicopathological data were then assessed to determine
whether there was a correlation with sLex tumour expression. Double labelled immunofluorescence staining was
performed to analyse the combined expression of sLex and E-Cadherin.
Results: sLex expression was consistently demonstrated in all cases of canine mammary carcinomas with different levels
of expression. We found a significant relationship between the levels of sLex expression and the presence of lymph node
metastases. We also demonstrated that when E-Cadherin expression was increased sLex was reduced and vice-versa.
The combined analysis of both adhesion molecules revealed an inverse relationship.
Conclusion: In the present study we demonstrate the importance of sLex in the malignant phenotype of canine
malignant mammary tumours. Our results support the use of sLex as a prognostic tumour marker in canine mammary
carcinomas. Furthermore, we showed that sLex and E-Cadherin expression were inversely correlated. Future studies are
warranted to clarify the molecular mechanism underlying the relation between sLex and E-Cadherin in canine mammary
carcinoma cells which represents an important comparative model to woman breast cancer.
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Background
Mammary tumours are the most common tumours in
intact female dogs and approximately 40% to 50% of
these tumours are malignant [1]. All malignant canine
mammary tumours have the potential to metastasise. In
general canine malignant tumours metastasise via the
lymphatics to the regional lymph nodes or hematoge-
nously to the lungs that represent the most common site
of distant metastases. [1-3]
Malignant transformation is associated with abnormal
glycosylation, resulting in expression of altered carbohy-
drate determinants, such as the Sialyl Lewis x (sLex) anti-
gen. Altered cell surface glycosylation is a prominent
feature of malignant tumour cells and define their inva-
sive and/or metastatic properties in general [4-12].
Tumour metastasis is a multistep process requiring
detachment of malignant cells from the primary tumour,
invasion of blood or lymph vessels, interaction with
endothelium, extravasation at distant sites and formation
of new tumour foci [9,12,13]. It is generally accepted that
every step of the metastatic cascade is dependent on spe-
cific adhesive interactions of cancer cells with other cells
and components of the extracellular matrix. These interac-
tions are mediated by different families of adhesion mol-
ecules including cadherins, integrins, members of the
immunoglobulin superfamily, and selectins and their car-
bohydrate ligands – Sialyl Lewis a (sLea) and sLex
[9,13,14].
sLex is a tetrasaccharide (NeuAcα2 → 3Galβ1 → 4[Fucα1
→ 3]GlcNAcβ1 → R) that is particularly relevant from a
biological standpoint. It is involved in selectin-mediated
adhesion of cancer cells to vascular endothelium and this
determinant is thought to be closely associated with
hematogenous metastases of cancer [12-17]
In humans, the expression of sLex is significantly increased
in carcinoma cells [4,7,18]. Many clinical studies have
shown an association between the expression of sLex on
tumours and enhanced tumour progression and metasta-
sis [7,19]. In woman breast carcinoma the presence of sLex
was also correlated with poor prognosis [20,21]. In fact,
the presence of sLex has been used as a prognostic tumour
marker in various types of human cancer [7,19], e.g. lung
[22], bladder [8], breast [20,21,23], prostate [24], colon
[25] and gastric [26-28] carcinoma. Little is known about
the expression of sLex in canine tumours. To the best of
our knowledge only the study of Nakagawa et al describe
the expression of sLex in canine and feline mammary
gland tumours [29], but no significant correlation
between the expression of sLex and prognosis has been
described in canine or feline tumours.
sLex and E-cadherin are two adhesion molecules that seem
to be involved in malignant progression with opposite
roles [31]. Alpaugh et al have described a cooperative role
between E-cadherin and sLex in the passive dissemination
of tumour emboli and in the genesis of the lymphovascu-
lar embolus of woman's Inflammatory Breast Carcinoma
[30-32].
Recently, Jeschke et al identified a negative correlation
between Sialyl Lewis antigens and E-cadherin expression
in woman breast cancer and their lymph node metastases
[23]. This combined analysis of tumour antigens involved
in adhesion of breast cancer cells has never been described
in canine mammary tumours, which constitutes an
important comparative model for woman breast cancer.
The purpose of the present study is to analyse, by immu-
nohistochemical staining methods, the expression of the
carbohydrate sLex  in canine malignant mammary
tumours and to evaluate the relationship between sLex
expression and tumour clinicopathological features. The
relation between the expression of the molecules sLex and
E-Cadherin [33] in canine malignant mammary tumours
was also investigated.
Methods
Tissue specimens
Fifty-three malignant mammary tumours and 102 local
and regional lymph nodes were surgically removed from
35 female dogs aged from 3 to 16 (mean, 9.9 years), of
various pure or mixed breeds. The specimens were fixed in
10% neutral buffered formalin. After dehydration and
paraffin wax embedment, sections of 4 µm were cut from
each representative paraffin blocks for staining with hae-
matoxylin and eosin (HE) and for sLex and E-cadherin
immunohistochemistry (IHC).
Lymph nodes were classified according to the presence of
cancer cells (positive or negative), using HE and cytokera-
tin IHC methods [33].
Histological examination of the tumours
Tumours, including benign proliferative lesions found in
the vicinity of the tumours, were classified independently
by two observers from HE-stained sections on the basis of
the diagnostic criteria of the World Health Organization
classification of tumours in domestic animals [34].
The presence of intra-tumoral necrosis was registered for
each case and evaluation and classification of the mode of
tumour growth was assessed as previously described [33].
Follow-up data
All animals were clinically evaluated every 3 months (by
physical examination, thoracic radiography and abdomi-BMC Cancer 2007, 7:124 http://www.biomedcentral.com/1471-2407/7/124
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nal ultrasound) for the presence of distant metastases dur-
ing a follow-up period of 2 years after surgery. All dogs
were followed until death or until the end of the observa-
tion period. In all dogs that died with suspected distant
metastases, complete necropsies were performed and his-
tological confirmation was obtained.
Immunohistochemistry
Canine mammary cancer tissues, which had been resected
by the curative operation were routinely processed and
used for immunostaining of sLex and E-cadherin.
Immunostaining was performed by the modified avidin-
biotin-peroxidase complex (ABC) method [35]. Two dis-
tinct monoclonal antibodies (mAbs) were used: the mAb
FH6 generated against sLex epitope [36] and the mono-
clonal mouse anti-human E-cadherin antibody (clone
4A2C7, Zymed, S.Francisco, California, USA) [33].
Tumour sections (4 um thick) were deparaffinized in
xylene, dehydrated through graded concentrations of eth-
anol and washed with distilled water. Sections were then
treated with Citrate buffer (sodium citrate antigen
retrieval solution; 10 mM citric acid, pH = 6) for 20 min-
utes in a microwave oven at 600 W. The slides were cooled
for 10 minutes at room temperature and rinsed twice in
Phosphate buffered saline (PBS) for 5 minutes. Endog-
enous peroxidase activity was blocked by treating the sec-
tion with hydrogen peroxide 3% in methanol for 10 min.
After washing the slides in PBS, non-specific staining was
eliminated by incubating the sections with normal rabbit
serum (Dako) diluted at 1:5 in PBS containing bovine
serum albumin (BSA) 10%, in a humid chamber for 20
min at room temperature. Excess normal serum was
removed and replaced by the anti-sLex mAb FH6 diluted at
1:5. After overnight incubation (≅18 hours) at 4°C, slides
were washed with PBS and incubated for 30 min with a
1:200 dilution of biotin-labelled rabbit anti-mouse sec-
ondary antibody (Dako). Sections were then washed with
PBS and incubated for 30 min with avidin-biotin complex
(Dako) diluted at 1:100. This was followed by staining the
sections for 5 to 7 minutes with 0.05% 3,3 diaminobenzi-
dinetetrahydrochloride (DAB) freshly prepared in 0.05 M
Tris/hydroxymethylaminomethane buffer, pH 7.6, con-
taining 0.1% hydrogen peroxide. Finally, sections were
lightly counterstained with haematoxylin, dehydrated,
and mounted.
Dilution of primary antibody, biotin-labelled secondary
antibody, and avidin-biotin complex were made with PBS
containing 5% BSA.
All series included, as positive control sections of a human
mixed gastric carcinoma previously shown to display
prominent expression of sLex.
Negative controls were performed by substitution of the
primary antibody with immunoglobulins of the same
subclass and concentration as the monoclonal antibody.
Scoring of immunostaining and statistical analysis
The degree of mAb FH6 reactivity with individual tissue
sections was scored by percentage of stained carcinoma
cells in the section by three authors (S.S.P., C.A.R., F.G.)
without knowing patients outcome and clinicopathologi-
cal features of the case. In the event of disagreement, slides
were reviewed by the observers, and a consensus was
obtained.
Expression of sLex and E-cadherin [33] in canine mam-
mary carcinomas were classified in the following manner:
negative, no immunoreactivity or immunostaining in very
rare cells; less than 25% of cancer cells stained; 25–50%,
well defined areas with positive cells; 50–75% of cancer
cells stained; and more than 75% stained cells. Scoring of
immunoreactivity was evaluated irrespectively of localiza-
tion of positive cells and intensity of the staining.
For statistical analysis the expression of sLex  was
regrouped in two percentual categories (<25% and ≥25%)
in order to increase the number of cases in each category
and in this manner improve the statistical power of the
tests.
The statistical relationship among variables was analysed
using tables of frequencies and their significance tested by
the Fisher's exact test [37]. P values less than 0.05 were
considered a significant association.
Double-labelling Immunofluorescence
For simultaneous visualization of sLex and E-cadherin on
the same tissue section, double-label immunofluores-
cence was performed. We chose the following representa-
tive tissue sections: sections with <25% sLex and >75% E-
Cadherin expression; sections with >75% sLex and <25%
E-Cadherin expression and sections with the same per-
centage of positive cells for both mAbs.
Paraffin sections were dewaxed, rehydrated and then
treated with Extran (Merck, Frankfurt, Germany) 0.05% in
distilled water for 10 min in a microwave oven at 750 W.
After cooled for 20 min at room temperature, slides were
rinsed twice in Phosphate-buffered saline (PBS) and then
incubated for 20 min in a humid chamber with rabbit
non-immune serum at a dilution 1:5 in PBS containing
bovine serum albumin (BSA) 10%. Sections were incu-
bated with the first primary mAb, anti-human E-Cadherin
(clone 36, BD Biosciences Pharmigen, diluted 1:100 in
PBS), overnight at 4°C. After washing twice for 5 min in
PBS, sections were incubated with FITC-conjugated rabbit
anti-mouse immunoglobulin (code F261; Dako, Glos-BMC Cancer 2007, 7:124 http://www.biomedcentral.com/1471-2407/7/124
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trup, Denmark; diluted 1:100 in PBS). Sections were
washed two times for 5 min in PBS and blocked with non-
immune goat serum diluted 1:5 in PBS containing BSA
10%. Sections were then incubated with mAb FH6
(mouse IgM) diluted at 1:5, overnight at 4°C. Sections
were washed two times for 5 min with PBS and incubated
with Texas red-conjugated goat anti-mouse IgM (Jackson
Immunoresearch) diluted 1:50 in PBS. Sections were
washed as before and nuclei were counterstained with 4'-
6-Diamidino-2-phenylindole (DAPI, Sigma) for 15 min
in the dark, diluted at 1:100 in PBS. Sections were washed
two times for 5 min in PBS and mounted with Vectashield
(Vector Laboratories, Burlingame, USA).
Dilutions of primary antibodies, secondary antibodies,
and DAPI were made with PBS containing 5% BSA.
Microscopy and image processing
Immunostained slides were examined under a fluores-
cence microscope (Leica DMIRE2) equipped with appro-
priate filters. Separate images for DAPI, Texas-Red and
FITC staining were captured digitally at ×200 and ×400
magnification. The red (for Texas-Red), blue (for DAPI),
and green (for FITC) components were merged and com-
posite images were imported into Adobe Photoshop 7.0®.
Results
Clinical and pathological features of mammary carcinoma 
patients
All dogs that were included in this study were female. The
mean age at surgery was 9.9 years old (range: 3–16 years
old). Histological diagnosis of canine mammary carcino-
mas consisted of 2 in situ carcinomas, 13 complex carcino-
mas, 13 tubulopappilary carcinomas, 9 solid carcinomas,
1 spindle cell carcinoma, 3 mucinous carcinomas, 10 car-
cinosarcomas and 2 carcinomas in benign tumour.
The mode of tumour growth was assessed in all of 53
tumours. Invasive tumours were more prevalent (28 cases,
52.8%) followed by expansive tumours (17 cases, 32.1%)
and tumours with vessel invasion (8 cases, 15.1%).
Lymph node metastases were evaluated in 50 tumours (in
3 cases the regional lymph nodes were not submitted).
The majority of the cases did not show lymph node metas-
tases (39, 78.0%) whereas eleven patients (22.0%)
revealed metastases in regional lymph nodes. The major-
ity of the cases that showed lymph node metastases were
classified as carcinosarcomas (6 out of 11). The others
were classified as complex carcinoma, tubulopapillary
carcinoma and solid carcinoma. From the eleven cases
that revealed nodal metastases, 4 patients revealed in
addition, distant metastases. Seven patients with lymph
node metastases died (in 4 animals was performed eutha-
nasia because of the tumour and 3 animals died of other
causes).
The presence of intra-tumoral necrosis was observed in
thirty tumours (56.6%), whereas 23 (43.4%) tumours did
not show this feature.
Of the 35 dogs that were included in this study, 33 com-
pleted the follow-up period and ten dogs (30.3%) devel-
oped distant metastases. From the 17 dogs that died at the
end of the follow-up period, 52,9% died because of the
mammary carcinoma and 47,0% died from other causes.
Expression of Sialyl Lewis x in canine mammary 
carcinomas
All of the carcinomas studied by immunohistochemistry
showed expression of sLex antigen (Figure 1). Thirty two
(60.4%) were found to express sLex in less than 25% of the
cells, whereas 21 (39.6%) showed sLex expression in more
than 25% of the cells. This distribution of sLex expression
include the early stage cases of canine mammary carcino-
mas such as in situ carcinoma and carcinoma in benign
tumour (Table 1). The staining was observed in the cyto-
plasm and/or in the cell membrane of epithelial cells. In
tumour areas with cellular squamous differentiation, sLex
was always expressed (Figure 2). In all cases, the adjacent
normal mammary gland tissue and the adjacent benign
proliferative lesions were evaluated and they did not
showed expression of sLex. It was analysed a total of 43
adjacent benign proliferative lesions (6 simple adenomas,
8 epithelioses and the others were hyperplasias in gen-
eral). In proliferative lesions sLex was expressed only in
mammary gland secretion.
Relationship between Sialyl Lewis x expression and 
clinicopathological features
Table 1 summarizes the expression of sLex according to
clinicopathological features.
No significant relationship was found between the expres-
sion of sLex antigen and the different histological types of
canine mammary carcinoma according to the World
Health Organization classification of tumours in domes-
tic animals [34].
Similarly, no significant relationship was observed
between sLex expression and the growth pattern of mam-
mary carcinomas.
A total of 63.6% of tumours with lymph node metastases
showed significantly higher sLex  expression (≥25%),
whereas most (74.4%) of the tumours without lymph
node metastasis showed underexpression (<25%) of sLex
(p = 0.034).BMC Cancer 2007, 7:124 http://www.biomedcentral.com/1471-2407/7/124
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Although this association did not reach a statistical signif-
icance, we observed that tumours without necrosis
showed less sLex expression than tumours with necrosis (p
= 0.07).
No significant relationship was found between the expres-
sion of sLex antigen and distant metastases.
Relationship between Sialyl Lewis x and E-cadherin 
expression
The analysis of expression of sLex and E-cadherin dis-
closed an inverse correlation among the two molecules,
higher sLex expression was accompanied with lower E-
cadherin expression and vice-versa (Figure 3). When
mammary carcinomas show underexpression of E-cad-
herin (<25%), all of them simultaneously revealed a
higher sLex expression (≥25%). On the other hand when
tumour samples showed overexpression of E-cadherin
(>75%) the majority of them (93.1%) simultaneously
revealed less than 50% of sLex expression. In summary, we
found a significant relationship (p = 0.013) between sLex
and E-cadherin expression in canine malignant mammary
tumours (Table 2).
Table 1: Relationship between Sialyl Lewis x expression and clinicopathological features in canine malignant mammary tumours.
Sialyl Lewis x expression
Clinical Features Number of cases(%) <25% ≥25% P value
Histological type (n = 53) NS(0,075)
In situ carcinoma 2 (3.8%) 1 (50.0%) 1 (50.0%)
Complex carcinoma 13 (24.5%) 12 (92.3%) 1 (7.7%)
Tubulopapillary carcinoma 13 (24.5%) 7 (53.8%) 6 (46.2%)
Solid carcinoma 9 (17.0%) 5 (55.6%) 4 (44.4%)
Spindle cell carcinoma 1 (1.9%) 1 (100.0%) 0 (0.0%)
Mucinous carcinoma 3 (5.7%) 1 (33.3%) 2 (66.7%)
Carcinosarcoma 10 (18.9%) 4 (40.0%) 6 (60.0%)
Carcinoma in benign tumour 2 (3.8%) 1 (50.0%) 1 (50.0%)
Mode of Growth (n = 53) NS(0,27)
Expansive 17 (32.1%) 13 (76.5%) 4 (23.5%)
Invasive 28 (52.8%) 15 (53.6%) 13 (46.4%)
Vessel invasion 8 (15.1%) 4 (50.0%) 4 (50.0%)
Lymph node metastases (n = 50)* 0.034
No 39 (78.0%) 29 (74.4%) 10 (25.6%)
Yes 11 (22.0%) 4 (36.4%) 7 (63.6%)
Necrosis (n = 53) NS(0,078)
Absent 23 (43.4%) 17 (73.9%) 6 (26.1%)
Present 30 (56.6%) 15 (50.0%) 15 (50.0%)
Distant Metastasis (n = 33) NS(0,24)
No 23 (69.7%) 17 (73.9%) 6 (26.1%)
Yes 10 (30.3%) 5 (50.0%) 5 (50.0%)
* No lymph nodes were submitted with 3 tumours
NS – Not significant (P > 0.05)
Immunohistochemical study of the expression of Sialyl Lewis  x in canine malignant mammary tumours Figure 1
Immunohistochemical study of the expression of Sia-
lyl Lewis x in canine malignant mammary tumours. 
A. Solid carcinoma; >75% of sLex expression; ×400 B. Carci-
nosarcoma; 25–50% of cells stained; ×400.BMC Cancer 2007, 7:124 http://www.biomedcentral.com/1471-2407/7/124
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Simultaneous expression of sLex and E-cadherin was ana-
lysed using double-label immunofluorescence method
(Figure 4), demonstrating the absence of overlapping
between the two molecules (Figure 4). Based on these
results, it seems that, when cells express sLex they do not
express E-cadherin, and on the other hand when they are
positive for E-cadherin they are negative for sLex.
Discussion
Malignant transformation of tumour cells is associated
with abnormal glycosylation, resulting in expression of
altered carbohydrate determinants including the expres-
sion of sLex and sLea antigens [4,9,12]. These carbohydrate
antigens have been shown to be useful tumour markers in
carcinomas of different organs [4,9,12]. The biosynthesis
of these oligosaccharides are usually increased and altered
during the acquisition of the malignant phenotype and
tumour progression [5,12]. Some studies refer that aber-
rant glycosylation is a result of initial oncogenic transfor-
mation, as well as a key event in induction of invasion and
metastases [10,12].
Most human carcinomas show changes within cell surface
carbohydrates compared to their normal counterparts
[4,12].
sLex, present on the surface of tumour cells has been
found to serve as ligands for endothelial E-selectin and
was shown to play a major role in the process of adhesion
of cancer cells to the endothelium [38]. sLex not only is a
marker for cancer but also is functionally implicated in
the malignant behaviour of cancer cells [4,12-14]. E-selec-
tin, one of the selectin family member is expressed on the
vascular endothelial cells and adheres to a carbohydrate
ligand, sLex [15,16]. Binding of sLex, present on the cell
membrane of neutrophil granulocytes, to E-selectin,
expressed on activated endothelial cells, was shown to ini-
tiate neutrophil extravasation and migration into tissues
[15]. It has been hypothesized that the E-selectin/sLex
interaction can mediate the sequence of adhesion of
tumour cells to endothelium and their subsequent
extravasation in a process that mimics the above process
Table 2: Relationship between Sialyl Lewis x and E-cadherin expression in canine malignant mammary tumours.
Sialyl Lewis x expression
E-Cadherin expression Number of cases (%) <25% ≥25% P value
<25% 5 (9.4%) 0 (0.0%) 5 (100.0%) 0.013
25–50% 7 (13.2%) 6 (85.7%) 1 (14.3%)
50–75% 12 (22.6%) 9 (75.0%) 3 (25.0%)
>75% 29 (54.7%) 17 (58.6%) 12 (41.4%)
Immunohistochemical expression of Sialyl Lewis x in squa- mous metaplasia Figure 2
Immunohistochemical expression of Sialyl Lewis x in 
squamous metaplasia. All cells that exhibit squamous 
metaplasia (arrows) are positive for Sialyl Lewis x. ×400
Relation between Sialyl Lewis x and E-cadherin expression Figure 3
Relation between Sialyl Lewis x and E-cadherin 
expression. The figure illustrates the negative correlation 
between sLex and E-Cadherin expression in canine malignant 
mammary tumours. When expression of E-cadherin increase, 
the expression of sLex decrease and vice-versa.BMC Cancer 2007, 7:124 http://www.biomedcentral.com/1471-2407/7/124
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of inflammation [15,17]. The sLex antigen is expressed by
various human carcinomas such as: gastric carcinoma
[26], colorectal carcinoma [25], lung cancer [22], prostate
carcinoma [24], bladder carcinoma [8], oral [39],
head&neck squamous cell carcinoma [40] and breast can-
cer [11,20,23]. The amounts of sLex expression are closely
associated with progression and with poor prognosis in
those cancers.
In canine cancers, Nakagawa et al has described the
expression of sLex in canine and feline mammary gland
tumours. However no association with clinicopathologi-
cal features and prognosis was observed [29,41].
The present study demonstrates that in malignant canine
mammary tumours the malignant transformation of the
mammary gland is accompanied by expression of sLex.
These results are in agreement with previous observations
showing that in squamous metaplasia, used as criteria of
malignancy in canine mammary cancer [42-44], there is a
strong expression of sLexantigen. These observations sup-
port the use of sLex as a prognostic tumour marker in
canine mammary carcinomas.
In this study, we found no significant relationship
between sLex expression and the histological type of the
tumours, classified according to World Health Organiza-
tion classification. This result is in agreement with the
results described by Nakagawa et al in canine and feline
mammary gland tumours [29]. Similarly, in woman
breast cancer, Nakagoe et al did not find an association
between sLex expression and histological type of the carci-
noma [20].
Previous studies have shown that, in woman breast can-
cer, tumour necrosis is associated with poorer survival
[45-47] and higher recurrence rates [46]. In canine mam-
mary tumours, the presence of large areas of necrosis
within the tumour mass could be used as criteria for a
diagnosis of malignancy [44]. In spite of no association
between sLex expression and tumour necrosis we observed
that some tumours with necrosis showed high amounts of
sLex expression.
It is clear that the expression of sLex in tumours is a marker
of the invasive and/or metastatic properties of the
tumours [4,11]. In addition, it has been shown that sLex
promotes binding of tumour cells at an invasion focus to
endothelial cells through E-Selectin [11]. Many clinical
studies show a clear association between the expression of
sLex and tumours with enhanced progression and metas-
tases [19]. In woman breast cancer, it was reported that
the expression of sLex antigen in tumour cells was associ-
ated with poorer prognosis [20]. Matsuura et al demon-
strated that the level of sLex was elevated in the sera of
patients with metastatic breast cancers [21]. Still in
woman breast cancer, Jeschke et al reports that overexpres-
sion of sLex was associated with poorer prognosis and
malignant relapse [23].
To date, the expression of sLex in canine malignant mam-
mary tumours, was not correlated neither with clinico-
pathological features, neither with prognoses [29].
In the present study we found a significant correlation
between sLex expression and lymph node metastases. To
the best of our knowledge, this is the first study to show
such a relationship in canine malignant mammary
tumours. These observations may suggest that sLex expres-
Double-label immunofluorescence of canine malignant mam- mary tumour (Complex carcinoma) Figure 4
Double-label immunofluorescence of canine malig-
nant mammary tumour (Complex carcinoma). A – 
Cells that are positive for Sialyl Lewis x (red) are negative for 
E-cadherin (green) and vice-versa. ×200 B – Absence of co-
expression of sLex and E-cadherin in the same cells. ×400BMC Cancer 2007, 7:124 http://www.biomedcentral.com/1471-2407/7/124
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sion may also play a role in the process of local lymphatic
invasion and metastization [38]. On the other hand, we
did not observe an association between sLex expression
and the development of distant metastases. This observa-
tion may suggest that in canine mammary tumours sLex
does not contribute to haematogenous metastasis. How-
ever we could not rule out that the absence of association
of sLex and haematogenous metastasis stems from the
small number of cases studied for this clinicopathological
feature.
These combined results from the relation between sLex
expression and the clinicopathological features allow us
to conclude that the sLex carbohydrate structure contrib-
utes for the malignant phenotype and tumour progression
of canine malignant mammary tumours.
Tumour cell dissemination and development of metas-
tases is a multistep process involving complex interaction
between cancer cells, extracellular matrix, the vascular sys-
tem, the immune system and the target organs [48]. Adhe-
sion molecules are contributory factors toward metastatic
activity. Adhesion can be divided into reduced adhesion
of tumour cell, tumour cell interaction and increased
adhesion of floating tumour cells to vascular endothelial
cells [48]. Recently we and other authors have described
that the loss of E-Cadherin expression may have prognos-
tic value in canine malignant mammary tumours [33,49].
In the present study, our results also showed that increas-
ing expression of sLex correlates with lymph node metas-
tases in canine mammary carcinomas. To address a
possible cooperative role between these two molecules
involved in cell adhesion, sLex and E-cadherin, we have
compared their expression in canine malignant mammary
tumours. Our results showed an inverse relationship
between sLex and E-cadherin expression. Cases expressing
sLex showed decrease E-Cadherin expression and vice-
versa. Similarly, we could observe in doubled labelled
immunofluorescence images, that cells that expressed sLex
were negative for E-cadherin and vice-versa. This observa-
tion is the first indication of a significant relationship
between sLex and E-cadherin expression in canine malig-
nant mammary tumours. Based on our results it seems
that the expression of sLex and/or E-cadherin on the same
tumour cell could be regulated by an internal mechanism
of the cell. In a previous study in a model of woman
Inflammatory Breast Carcinoma (IBC), Alpaugh et al have
described a cooperative role of E-cadherin overexpression
and sLex underexpression in the genesis of the lymphovas-
cular embolus of IBC [30,31]. These results showed that
both types of adhesion molecules might play opposing
roles within the same tumour cell model. Furthermore,
Jeschke et al have also shown, in breast cancer, a negative
correlation between the expression of Sialyl Lewis anti-
gens and E-cadherin as the risk of breast cancer metastasis
progresses [23].
Our findings, in canine mammary carcinomas, supports
the generally accepted dogma that metastatic propensity is
an active biologic process that includes the decrease of
tumour cells adhesion at the primary tumour site (E-cad-
herin down-regulation) which is thought to be accompa-
nied by higher mobility and invasiveness [50]
contributing to the process of local lymphatic invasion
and metastization (sLex overexpression).
Conclusion
Our results demonstrate the importance of sLex in malig-
nant phenotype of canine mammary carcinoma and sup-
port the use of sLex as a prognostic tumour marker in
canine malignant mammary gland tumours.
The significant relation between sLex and lymph node
metastases allow us to conclude that sLex can be used as
prognostic factor in canine malignant mammary
tumours.
There is an inverse relationship between the expression of
the adhesion molecules sLex and E-cadherin, in canine
mammary carcinomas.
The present results warrants further investigation address-
ing the clarification of the molecular mechanism deter-
mining this inverse correlation between sLex  and E-
cadherin as well as the investigation of the mechanisms by
which sLex interferes with homotypic cellular adhesion
mediated by E-cadherin in canine malignant mammary
tumours, as a comparative model to woman breast cancer.
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